Axxam S.p.A. announces the merger of its two German subsidiaries into Axxam GmbH
Under the new name we will continue to offer our competences, resources and experience to our customers and partners supporting their research projects and facing together the new challenges with a joint and integrated approach. Axxam GmbH is structured into two business units, namely Discovery Services Constance (“DSC”) and IMAX Discovery, deriving respectively from the two original companies. Dr. Thilo Enderle will continue in his role as Managing Director of Axxam GmbH and will lead the DSC business unit, while Dr. Marcel Winning will continue to lead the IMAX Discovery business unit.
Offering high-quality services including high-throughput screening (HTS) with plate optical detection (in 1536 and 384 well formats) and complementary technological readouts such as radiometric screening (SPA, flash-plate), the DSC business unit will cooperate in unison with the team in Milan responding to the increasing requests from the market for capacity and capabilities in early drug discovery research and specifically in facing challenging HTS projects.
The IMAX Discovery business unit will continue offering its clients and partners integrated solutions across the entire discovery process starting from flavor, fragrance and cosmetic target identification and validation up to the selection and development of new bioactive compounds by providing services, tools and integrated solutions tailored to the specific needs of its clients and
The decision to merge our German subsidiaries and to adopt the Axxam brand in Germany is in line with our strategy to strengthen our presence and investments in Germany and to offer to the several clients and partners integrating capacity and capabilities in early discovery research. Furthermore, this will smoothen the intercompany processes increasing efficiency and having access to broader capacity and an integrated set of competences with significant benefits for our clients’ research projects.